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BACKGROUND: Extracellular vesicles (EVs) are a diverse group of membrane-bound nanovesicles 
potentially released by every cell. With the li er s unique ensemble of cells and its fundamental 
physiological tasks, elucidating the role of EV-mediated hepatic cellular crosstalk and their role in 
different pathologies has been gaining the attention of many scientists. 
SCOPE OF REVIEW: The present review shifts the perspective into practice: we aim to critically discuss 
the methods used to purify and to biochemically analyse EVs from specific liver resident cells, including 
hepatocytes, hepatic stellate cells, cholangiocytes, liver sinusoidal endothelial cells, Kupffer cells, liver 
stem cells. The review offers a reference guide to current approaches. 
MAJOR CONCLUSIONS: Strategies for EV isolation and characterization are as varied as the research 
groups performing them. We present main advantages and disadvantages for the methods, highlighting 
common causes for concern, such as FBS handling, reporting of cell viability, EV yield and storage, 
differences in differential centrifugations, suboptimal method descriptions, and method transferability. 
We both looked at how adaptable the research between human and rodent cells in vitro is, and also 
assessed how well either of them translates to ex vivo settings. 
GENERAL SIGNIFICANCE: We reviewed methodological practices for the isolation and analysis of 
liver-derived EVs, making a cell type specific user guide that shows where to start, what has worked so 
far and to what extent. We critically discussed room for improvement, placing a particular focus on 























Extracellular vesicles (EVs) is a collective term referring to a diverse group of small membrane vesicles 
virtually released by all cell types, and which are generally being categorized according to their 
biogenesis:[1,2] apoptotic bodies are blebs of the dying cell membrane and have the broadest size 
range; microvesicles, sometimes referred to as microparticles or ectosomes, stem from the outward 
budding of the cellular membrane. Exosomes, which tend to be the smallest subpopulation, are released 
into the extracellular space after multivesicular bodies (MVB) fuse with the cell membrane (Figure 1).   It 
is still not really possible to isolate one subpopulation from the others, and while it is believed that they 
may display biomolecules that are enriched to different extents, their overlapping composition, density 
and size, as well as the absence of subtype-specific markers still make for a considerable challenge.[3,4] 
The recent discovery of their role in intercellular communication captivated the attention of a growing 
number of scientists anticipating the enormous potential of EVs in the fields of diagnostics and drug 
delivery.[5,6] For some pathological dispositions EVs can be applied as liquid biopsies, and that has 
sparked a lot of interest from a diagnostic perspective. EVs are enriched in selected biomolecules, they 
are intrinsically equipped to protect their cargo from degradation, and while their complexity offers many 
characterization opportunities (see Figure 1), they are still simpler to analyse than total blood or serum 
samples. The interest in EVs as drug delivery systems stems from their potential advantages over 
synthetic carriers: they are bioavailable, biocompatible, resistant to RNAases and proteases (high 
physicochemical stability), capable of long-distance communication and they are intrinsically able to 
interact with cells even across species.[7 9] 
 
 
Figure 1: EV nomenclature according to biogenesis; zoomed insert shows a schematic representation of 





The increasing scientific interest in EVs[10] has led to the establishment of dedicated, open access 
databases such as Vesiclepedia,[11] EVpedia[12] and EV-TRACK,[13] which are being regularly 
updated. The majority of the information is concerning proteins, whereas EV-TRACK sets itself apart by 
focusing on method transparency. 
As reviewed elsewhere,[14,15] there are significant challenges (small yields, co-purification of 
contaminants, etc.) in finding the most efficient protocols for the isolation and sufficient characterization 
of EVs. We will discuss them in an effort to encourage sharing the current knowledge of the more 
practical scientific trends in those areas, starting with the present review on liver-derived EVs. 
 
The liver is a large and complex organ responsible for a variety of essential physiological tasks including 
protein synthesis, lipid storage regulation, xenobiotic detoxification, and offering support to both 
immunological activity and food digestion.[16] It is difficult to understate its importance. When organ 
function is compromised, hepatic diseases are directly responsible for as many as 2 million deaths per 
year: liver cirrhosis alone kills 1.16 million people every year, and hepatocellular carcinoma accounts 
for the death of 788 000 more, meaning that combined they cause 3.5% of all yearly deaths in the 
world.[17,18] The global health burden of liver associated conditions is not sufficiently addressed as of 
yet.[19] With its unique ensemble of diverse cells (see Figure 2), the liver offers the opportunity to study 
intra- and inter-cellular communication. Elucidating the role of EV-mediated hepatic cellular crosstalk 
has gained the attention of many researchers, who have been able to review its critical role in both 
health and disease, pointing to differences in the set of EVs that are released, especially in the case of 






Figure 2: Liver location, structure of hepatic lobules (adapted with permission[26]) and their anatomy at 
the cellular level: hepatocytes (the most abundant cells in the liver and responsible for the most tasks, 
see chapter 2), hepatic stellate cells  (vitamin A storing cells, chapter 3), cholangiocytes (modifying the 
bile along the bile ducts, chapter 4), liver sinusoidal endothelial cells (lining the fenestrated layer of blood 
vessels, chapter 5), Kupffer cells (liver resident macrophages, chapter 6), liver stem cells (potentially 
playing a role in liver regeneration, chapter 7). 
 
The present review shifts the perspective into practice: we aim to critically consider the methods used 
to purify and to biochemically analyse EVs from specific cells, offering a user/reference guide to current 
practices (see Table 1). The most common and (when applicable) the most original/promising protocols 
will be examined in order to provide a discussion frame. Diving into the different methodological 
approaches, we will also highlight limitations and possible inconsistencies. Finally, the (interspecies) 
method transferability and the translational applicability of these practices will be examined. We will look 
within the individual cell specific chapters if the same or similar methods could be transferred to different 
in vitro systems (rodent cells, co-cultures), but we will also explore the practical strategies for EV-
isolation and characterization that were applied ex vivo and in the clinic from patients with liver-related 
conditions (chapter 8). It is worth noting, that we are only covering method employment and it is not our 
role to comment on the quality of the results gained from them. As to the nomenclature, we strived to 
keep it as it as applied in the referenced manuscripts, onl  changing it to EVs  if e needed to 
paraphrase, since it is the preferred generic term.[1,2]
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2. EVs from Hepatocytes  
 
Hepatocytes are the most abundant cells in the liver, comprising about 70-80% of its mass, they are 
dedicated to protein synthesis (serum albumin, transferrin and other glycoproteins), while also being the 
main site for glycolysis and only site for bile salts production in the body.[222 224]  Another essential 
task relying on hepatocytes is detoxification: they metabolize both exogenous (e.g., drugs, toxins) and 
endogenous (e.g., steroids) compounds.[225,226] More notable still is their ability to regenerate the 
injured liver.[227] Given their prominent presence, their multifaceted roles, and their direct association 
to many liver diseases (fatty liver, chronic hepatitis, non-alcoholic fatty liver disease, non-alcoholic 
steatohepatitis, liver fibrosis, hepatocellular carcinoma),[228] it is not surprising that they have been the 
most frequent focus of research involving liver-derived EVs so far. 
 
2.1 Isolation strategies 
 
EVs have been isolated from both cryopreserved primary hepatocytes[54,60,179,212] as well as from 
cell lines (see Table 1).  
Berardocco et al. 2017[27] isolated EVs from Hep3B, HepG2, Huh7 and HuH6 human hepatocarcinoma 
(HCC) cell lines by differential centrifugation: first cells were removed (300 x g, 10 min), then apoptotic 
bodies (2 000  g, 30 min), and finally cell organelles (16 000  g, 20 min). EVs were then pelleted by 
ultracentrifugation (UC; 120 000  g for 70 min) and the EV-enriched pellet was resuspended in PBS 
and purified by repeating the UC step. Everything was performed at 4 °C, and the final EV-pellet was 
drained, rapidly frozen in liquid nitrogen and stored at -80 °C before analysis. Cells were grown in cell 
culture medium supplied with 10% FBS, but EVs were isolated after having it exchanged with medium 
containing 1% FBS and 0.25% human serum albumin (hBSA), both of which had been previously 
depleted of EVs by UC (120 000  g for 5 h). We appreciated the care that was taken to depleting FBS 
and hBSA of EVs prior to use; experimental corroboration on the chosen protocol was missing, yet it 
has been previously reported that even 18 h long UC is not necessarily effective to remove all FBS-
EVs.[229]  
As to the isolation of the hepatocyte derived EVs themselves, other groups worked similarly, but 
preferred different centrifugation times and forces (e.g. Cannito et al. 2017:[48] 3 000 x g for 15 min, 
then UC at 100 000 x g for 90 minutes at 10 °C). Why some numbers were chosen over others is rarely 
explicitly justified: sometimes it is disclosed that previously reported methods have been adopted (e.g. 
Fang T. et al. 2018[38] citing Lässer et al. 2012[230]), and oftentimes published practices were adapted 
without explaining what prompted the tweak. A direct experimental validation could not always be found, 
which is a major weakness of these protocols. 
He et al. 2015[56] added a filtration step (0.22 m) that followed their differential centrifugation (500 x g 
for 10 min, then 16 500  g for 30 min) and preceded the UC (110 000  g, 70 min). After this, the EV-




was followed by yet another UC wash in PBS. The protocol seemed to address the concern that UC can 
lead to co-isolation of other impurities (protein aggregates, lipoproteins) more carefully. 
Others avoided UC by favoring commercially available precipitation kits such as ExoQuick [50,54,216] 
and Total Exosome Isolation  (TEI).[43,58] These kits have been suggested to be more easily 
translated into clinical settings because not every hospital has an ultracentrifuge, the required 
accessories, and the specifically trained personnel, and they occasionally yield more and even more 
pure EVs,[231] although there are still conflicting reports about it.[232,233]However, they come with 
their own set of perplexities: different precipitation kits are commercially available, but their composition 
being proprietary information makes it hard to evaluate their efficacy in excluding contaminants and in 
their ability to work with EVs from any cell type.   
Yet another approach was to opt for membrane affinity spin columns such as ExoEasy Maxi , opted 
by Cao et al. 2019.[167]   
It is worth pointing out that the storage strategy is not always disclosed, let alone the validation thereof. 
Similar to Berardocco et al. 2017, EV pellets were stored at -80 °C by other groups 
too,[28,29,31,37,40,50,51,53,63,69,206,213] mostly after re-suspending them in PBS (when the final 
volume is shared, it tends to be between 50 and 500 L), or at -70 °C.[39] We particularly appreciated 




When evaluating the quality of the isolation methods, we would like to point to the approach of Thacker 
et al. 2018,[45] who tested different protocols, directly comparing them to UC: ExoQuick  was shown 
to lead to the highest co-purification of extravesicular contaminants, while OptiPrep  yields were 
deemed too low. They describe culturing HepG2 in T75 flasks, 2.1 million cells/mL in 10 mL at seeding, 
and harvesting EVs after 2-3 days, starting from 4 mL of cell culture medium and calculating back the 
number of particles/mL for yield comparisons (1011 p/mL by ExoQuick , 1010 p/mL by UC). It would 
have been beneficial to report the number of cells and their viability at the time of medium collection to 
use the method performances for future comparisons of protocol efficiency, not only efficacy. This would 
allow to   find whether EVs can be isolated by a certain approach, but also to evaluate how many EVs 
can be retrieved from a specific number of cells, and how viable the cells were at the time of EV collection 
to minimize concerns about isolation of apoptotic bodies. Tentative quantification by other groups, when 
reported, was sometimes shown as relative release after measuring concentration by nanoparticle 
tracking analysis (NTA),[46,63,234] better still by normalizing it to cell number.[56,210] Others favoured 
protein quantification[31,37,43] (even normalizing it to a number of cells[60]), or counting EVs as seen 
by EM.[52] Little attention was given to explicitly stating the cell viability; exceptions include Eguchi et 
al. 2017,[36] reporting on 90.5 - 94.5% cell viability, and Xiao et al. 2010[30] documenting 95%. 
The intrinsic uncertainty associated with isolation and purification techniques makes the characterization 
steps all the more important. We found Berardocco et al. 2017,[27] again to be  thorough in their 
approach using gel electrophoresis for protein profiling, atomic force microscopy (AFM) for morphology 
and size, and a previously developed colorimetric nanoplasmonic assays (see Maiolo et al. 2015[235]) 




acid (BCA) assay and western blot analysis was done for EV and non-EV markers (GM130, calnexin, 
Hsp70, CD63, CD9, TGM2, EpCAM, E-cadherin, LGR5 and -actin). Total RNA from EVs was purified 
using the Fatty Tissue RNA Purification kit, SOLiD Library preparation, sequencing and bioinformatic 
analysis was done by GENOMNIA. 
Other groups have favoured dynamic light scattering (DLS) for EV-size determination,[36,48,57] 
tuneable resistive pulse sensing (TRPS, i.e. qNano ),[56] nanoparticle tracking analysis (NTA; for size 
and concentration),[37,38,49] transmission electron microscopy (TEM)[28,29,33,35,37 40,47
50,53,60,69,188,208] (sometimes combined to immunogold staining of EV 
markers),[30,31,41,46,52,56,58,180,214] or cryo-TEM (for size and morphology)[187,193,194,236] and 
even scanning EM (SEM).[43] Quantification and marker expression analysis of EVs by flow cytometry 
was also done[28,40,41,47 49,54,213,215] (e.g. Cobb et al. 2018,[54] using a kit for exosome 
immunocapture and colorimetric quantification). Proteomic analysis on hepatocyte-derived EVs was 
performed to various degrees by several groups, we will only mention a few;[35,61,174] the same 
applies to total and specific RNA evaluations.[36,51,52,216] Lipidomics characterization was found in 
the study by Kakazu et al. 2016,[69] who looked at ceramides and non-esterified Fas (cell surface death 
receptor) by mass spectrometry (MS). Finally, Wu et al. 2018[60] reported an EV zeta potential between 
-20 and -30 mV. 
 
2.3 Interspecies method transferability 
 
Different groups have retrieved hepatocyte-EVs originating from mice and rats and we would like to 
highlight those providing comparison to human cells. 
Povero et al. 2013[41] compared HepG2 to rat-derived hepatocyte-EV, isolating them by differential 
centrifugation (including UC) and, for selected experiment, further purified them by 10 to 70% sucrose 
gradient UC (150 000  g, 18 h, 10 C). Eguchi et al. 2017[36] had isolated by UC EVs from HepG2 and 
from primary mice hepatocytes, as well as blood-EVs from mice plasma. A few researchers used the 
Huh7 cell line, again looking at EVs released from mice hepatocytes after isolating them by 
UC.[63,69,180] When looking at increasing the complexity of the analyzed system without going in vivo 
still, we would like to single out Dioufa et al. 2017,[237] for using their own ex vivo human liver 
microphysiological system (MPS), developed with primary hepatocytes and non-parenchymal cells 
(NPCs) from the liver. EVs from the liver MPS were isolated by polymeric precipitation with the TEI kit, 
and they were then analyzed by TEM and for total RNA, as well as for cDNA and miRNA; exosomes 
markers were evaluated by western blot using the Exo-CheckTM exosome antibody array). More 
interesting still, some managed to compare human hepatocytes cell lines to primary rodents cells as 
well as samples obtained from human donors within the same study (see chapter 8).[32,62,63]  
 





Hepatic stellate cells reside in the space of Disse (Figure 2), between hepatocytes and endothelial cells, 
and are mainly responsible for storing vitamin A in cytoplasmic lipid droplets.[238] Upon liver injury, 
however, they undergo transdifferentiation into a myofibroblast-like state, i.e., they become activated, 
progressively lose their lipid droplets and start promoting fibrogenesis, most notably by deposition of 
excessive and collagen rich extracellular matrix.[239,240] When the injuries are repeated during chronic 
diseases and the fibrosis is not resolved, the excessive deposition of scar tissue eventually leads to 
cirrhosis and the loss of organ function. The pivotal role of HSCs in liver fibrosis makes these cells 
crucial therapeutic and diagnostic targets.[241] 
 
3.1 Isolation strategies 
 
For the in vitro isolation of HSC-derived EVs, a common cell line seems to be the LX-2, which has the 
advantage of being able to grow under serum free conditions.[242] 
Brandon-Warner et al. 2016[70] isolated EVs from cell culture medium using the ExoQuick  
precipitation kit, after culturing the cells with 10% of commercially available Exo-free FBS. Information 
about cell number and viability at the time of EV-collection and the total yield are missing, making it hard 
to judge the efficiency of their method. Purification steps after this were not performed and it is not 
specified how EVs were stored between isolation and analysis.  
Serial centrifugation was the preferred method for Chen L. et al. 2014, Charrier et al. 2014 and Wang 
et al. 2018.[71,72,243] Cell culture medium for EV-isolation had been prepared without FBS, and the 
LX-2 cells were serum-starved for 48-72 h but a measure of cell number, density and viability is 
unfortunately missing. The specific isolation protocols were found inconsistent, because Charrier et al. 
2014 refer their readers to Chen L. et al. 2014, which in turn cite Thery et al. 2006,[244] an overview of 
different protocols for the isolation of EVs. While the projects described in these articles were not 
focusing on the EVs isolated from HSCs, more descriptive protocols would better facilitate 
reproducibility. Wang et al. 2018[243] adapted an e osome  isolation procedure based on 
cholangiocytes and previously reported in Li L. 2016,[245]. Unfortunately, Li et al. refer to yet another 




Brandon-Warner et al. 2016[70] investigated total RNA, which was isolated using the SeraMiR  
exosome RNA purification kit, then quantified and analysed it to compare differences in the expression 
levels of individual miRNAs in cells and exosomes. 
Charrier et al. 2014[71] characterized their isolated EVs by electron microscopy, expression of key 
markers and size, based on protocols from  Thery et al. 2011[246] and Chen et al. 2014.[72]  The latter 
explains their characterization steps for HSC-EVs isolated from mice, adding that similar procedures  
were used for EVs originating from LX-2 cells. They performed western blots (CD9), TEM, DLS analysis, 
zeta potential measurements, and analysed exosomal and cellular RNAs for the presence of miR-21, 




While not as frequently explored as hepatocyte-derived EVs (see chapter 2), HSC-EVs have been 
analysed by a diverse array of means. Reporting of the protocols frequently relied on additional 
references to be looked up across different papers, which can complicate the ease with which reported 
methods could be reproduced.  
 
3.3 Interspecies method transferability 
 
There are even more examples for research involving murine and rat HSC-derived EVs than their human 
counterpart. In Chen L. et al. 2015,[78] Chen L. and Brigstock 2016[76] and Chen L. et al. 2016[75] EVs 
were purified as described in Chen L. et al. 2014[72] (differential centrifugation and UC, referring the 
reader to Thery et al. 2006[244]) from primary mice cells. EVs were analysed by NTA, and imaged by 
cryo-TEM.  Exosomal mRNA was determined by quantitative RT-PCR, while cellular EV-uptake was 
observed by confocal microscopy (EVs were stained with PKH26). Exosomal proteins were evaluated 
by western blot. Within this study (Chen et al. 2014), they also looked at circulating EVs but changed 
their isolation method. EVs were harvested from murine sera using PureExo Exosome Isolation Kits. 
Total exosomal RNA from sera was prepared using miRNeasy mini kits. 
Povero et al. 2014[20] and Witek et al. 2009[74] used primary rat HSCs: the former opted for differential 
centrifugation (including UC, as applied to HepG2, see chapter 2), while the latter preferred polymeric 
precipitation (TEI). Lambrecht et al. 2017[77] evaluated EVs from mice HSCs and those found in human 
plasma (see chapter 8).  
A rigorous parallelization of isolation and characterization practices is missing, but research with HSC-
derived EVs has been steadily gaining attraction, and their biochemical properties as analysed from 
rodent models are being increasingly explored in more complex settings. 
 
4. EVs from Cholangiocytes 
 
Cholangiocytes are epithelial cells lining the bile ducts (Figure 2), which can differ in size and 
morphology just as the bile duct tree itself does. Their main physiological role is the modification of the 
bile coming from the liver while it is being transported along the biliary ducts into the intestine.[247 250] 
Pathologies directly associated with cholangiocytes include primary biliary cholangitis, and primary 
sclerosing cholangitis, for  which liver transplantation is the only available cure.  Primary sclerosing 
cholangitis also leads to different cancers collectively known as cholangiocarcinoma.[250 252] 
 
4.1 Isolation strategies 
 
Cholangiocyte-EVs were preferentially isolated by serial centrifugation followed by UC. Sato et al. 
2017[80] used the H69 cell line, cultured with FBS that had been depleted of EVs b  UC (120 000  g, 
18 h). For EV isolation, they first removed cell debris (300 x g for 10 min, then 3 000  g for 30 min), 




ashed ith 30 mL PBS, pelleted again b  UC (120 000  g, 2 h) and re-suspended in 0.5 mL PBS. The 
adopted strategy of performing a filtration followed by PBS washes indicates a concern EV-purification. 
The description of the methods shows an attention to details that enable reproducibility, such as sharing 
the volume of PBS used to re-suspend the final pellet, which also helps put the yield as shown in the 
NTA distribution profiles into perspective.  
A slightly different approach was found in Arbelaiz et al. 2017,[79] which used the H69, EGI1 and TFK-
1 cell lines as well as patient blood (see chapter 8). Cell culture medium as centrifuged (1 500  g, 15 
min, 4 C), the supernatant filtered (0.22 m), and centrifuged again (10 000  g, 30 min, 4 C) before 
t o UC steps (100 000  g, 75 min, 4 C). Samples were store at -80 °C. It was not possible to 
extrapolate an absolute yield making comparison of EV-retrieval difficult. 
 
4.2 Characterization  
 
To determine the size and concentration of the isolated EVs, NTA and TEM were performed both by 
Sato et al. 2017 and by Arbelaiz et al. 2017; however, the latter additionally analyzed the EVs  protein 
profile by mass spectrometry, and evaluated the expression of different EV-markers (CD9, CD63, CD81) 
by western blot. Research articles about cholangiocyte-derived EVs are more limited in numbers rather 
than in quality, already providing fruitful isolation protocols and an ample baseline of analytical 
characterizations to build upon. 
 
4.3 Interspecies method transferability 
 
Centrifugation and UC proved to be a viable strategy for the isolation of EVs from mice cholangiocytes 
too. Witek et al. 2009[74] performed it when working with the 603B cells, after 16 h of serum starvation 
by first  removing cells and debris (2 000  g, 15 min, t ice) and then pelleting of EVs b  UC (50 000  
g, 45 min, twice). For selected experiments they would add a purification step by sucrose gradient 
centrifugation (100 000  g, 15 h). Fresh samples were analyzed for proteomics or they were stored at 
4 °C for no longer than 72 h before performing TEM and RNA analysis. 
Li X et al. 2018[81] worked with murine large and small cholangiocytes (MLEs, MSEs) and they cleared 
conditioned cell culture medium from cell debris b  centrifugation (2 000  g for 15 minutes follo ed b  
16 000  g for 20 min, both at 4 C), and pelleted EVs b  UC (100 000  g, 70 min, at 4 C). EVs were 
resuspended in sterile PBS and stored at -80 °C for further analysis. EV-size was determined by DLS 
and confirmed by TEM, and levels of mRNA H19 were assessed. Interestingly, they also isolated EVs 
from mice (and human) sera too, as further described in chapter 8. 
 
5. EVs from Liver Sinusoidal Endothelial Cells 
 
Liver sinusoidal endothelial cells (LSECs) form the fenestrated endothelial layer at the interface between 




particles that are smaller than 0.2 m, making them the central players in clearing the body of blood-
borne viruses.[253,254] When working with EVs from LSECs, researchers were interested infections 
caused by hepatitis B and C viruses (HBV and HCV). 
 
5.1 Isolation strategies 
 
EVs were isolated from primary LSECs and from the immortalized TMNK-1 cell line by Giugliano et al. 
2015,[82] using the ExoQuick  precipitation kit.  
Li J et al. 2013[83] preferred serial centrifugations: 300  g for 10 min, 2 000  g for 10 min, 10  000  g 
for 30 min; EVs were then pelleted by UC (100 000  g for 70 min), washed in PBS and pelleted by UC 





The characterization of LSEC-EVs in Giugliano 2015 was limited to the determination of total protein 
content by BCA and to detection using CD63-labeled Dynabeads. Beadbound EVs were labeled with 
anti-CD63-PE and anti-CD81-PerCP-eFluor 710 and finally quantified by flow cytometry. 
Li J et al. 2013 quantified the protein content by Bradford assay, and characterized the EVs by electron 
microscopy, by immunoblot for exosomal (CD63, TSG101, Ali , LAMP2, -actin, Hsp90) and non-
exosomal markers (GRP94, EEA1, Cytochrome C), and by microarray analysis of exosomal mRNA and 
miRNA.  
While restricted to a few research articles, EVs from LSECs have been successfully purified and 
characterized. Follow up research could expand the field by providing more insights into optimized 
storage strategies or yield determination practices that would allow for comparisons across studies. 
 
5.3 Interspecies method transferability 
 
When looking at the protocols applied to studying LSEC-derived EVs from rodents, Wang et al. 
2015[255] compared EVs isolated from a mice immortalized LSEC cell line (TSEC[256]) to murine 
serum-derived exosomes. The description of isolation and purification methods referred the reader to 
Huebert et al. 2010,[256] Thery et al. 2006,[244] Tu et al. 2015,[257] whose protocols were not related 
to EVs from LSECs. 
LSECs were cultured in medium with 10% FBS, which was prepared with 20% FBS first and then 
depleted of FBS-EVs by UC and sterile filtration. EVs were characterized by NTA, immunogold-EM 
(CD81, TfR, CD63) and western blot. They also mention using 50 g of e osomes per e periment, as 
determined by Bradford assay, although an exact number of cells required to achieve such a yield was 





6. EVs from Kupffer Cells 
 
The resident macrophages in the liver, found in the hepatic sinusoid, are known as Kupffer cells.[258] 
Since the liver is frequently in contact with exogenous material, suppressing un anted  immune 
responses is essential. Kupffer cells have been shown to provide anti-inflammatory signals that allow 
homeostatic immunological tolerance under healthy conditions. As part of the innate immune system, 
these macrophages phagocyte invading pathogens and play a critical role for the initiation of 
immunological responses when inflammation and recruitment of other cells becomes required by the 
triggered defence mechanism.[259 261] Dysregulation of these processes is directly connected to 
pathologies discussed in previous chapters, because Kupffer cells communicate through EVs  with 
hepatocytes, HSCs, Cholangiocytes and LSECs. 
  
6.1 Isolation strategies 
 
Aucher et al. 2013[85] chose the THP-1 cells as their model for liver macrophages, collecting their 
apoptotic bodies and exosomes. The isolation methods was adapted from Hristov et al. 2004[262]  with 
800 x g for 10 minutes to remove (endothelial) cells and then pelleting of apoptotic bodies at 16 500 x g 
for 20 min. For the isolation of the exosomes it cites the work of Mittelbrunn et al. 2011.[263] The latter 
stated that donor cells (T cells) were cultured with 10% FBS (depleted of bovine EVs by UC at 100 000 
x g overnight). Still Mittelbrunn et al. 2011 explain how the conditioned cell culture medium was cleared 
by centrifugation (320 x g, 5 min); the resulting supernatant was filtered through 0.22 m membranes, 
and EVs were finally pelleted b  UC (100 000  g, 60 min, 4 C). While the methods could be 
extrapolated, the reliance on references for method description sometimes risks to undercut all the work 
that was done. Ideally, the methods for EV isolation should also be experimentally validated for every 
new cell type regardless.   
Li J et al. 2013[83] and Saha et al. 2016[86] also used THP-1 cells to model Kupffer cells, as well as 
primary human monocytes. Saha et al. 2016 (who cultured cells using commercially available ExoFree-
FBS ) opted for EV-precipitation with ExoQuick , which was performed after two centrifugations 
(1 500  g for 10 min, then 10 000  g for 20 min) follo ed b  one filtration (0.8 m) step. 
Polymer precipitation was the strategy for Zhou et al. 2016,[87] although TEI kit was preferred. The cells 




Saha et al. 2016 analyzed THP-1-derived EVs by NTA for size and concentration, and determined the 
protein content by Bradford assay. Li J et al. 2013[83] analyzed protein content by Bradford as well, but 
they additionally performed EM, immunoblot analysis of exosomal markers, and microarray analysis of 




Zhou et al. 2016 characterized their isolated EVs by EM, western blot for both EV and non-EV markers 
(Alix, LAMP2, cytochrome c, HSP70, CD63, GAPDH) and immunofluorescence; macrophage-EVs were 
labelled with the PKH67 dye, then given to Huh-7 cells and observed by fluorescence microscopy.  
Future reports about EVs from Kupffer cells can expand the existing literature by providing additional 
insights into storage and yield optimization practices. 
 
6.3 Interspecies method transferability 
 
While Eguchi et al. 2017[36] had been very thorough in their analysis of hepatocyte-EVs (FACS, DLS, 
TEM, miRNA, see chapter 2), they also took a look at the EVs shed by hepatic macrophages they 
isolated from mice, and compared the two in terms of morphology (TEM) and concentration (FACS). 
Nojima et al. 2016[65,66] reported working with EVs originating from mice Kupffer cells. The EVs were 
isolated by differential centrifugation (300  g for 10 min, then 16 000  g for 30 min), after hich the 
supernatant as filtred through a 0.22 m membrane. EVs ere subsequentl  collected after t o UC 
steps (120 000  g for 70 min). The EV-pellet was re-suspended in PBS and purified on a 
Tris/sucrose/D2O densit  cushion UC (100 000  g for 90 min). EVs ere then transferred into a ne  
tube, and collected after one final UC step (120 000  g for 70 min). EV ields under different conditions 
were precisely reported, as well as the activity of neutral ceramidase and sphingosine kinase. 
 
7. EVs from liver stem cells 
 
Several studies have suggested the presence of liver-resident stem cells, which along with hepatocytes 
contribute to liver regeneration, but it remains a controversial topic, as reviewed elsewhere.[264] The 
identification of oval cells and their role in liver regeneration contributes to our current understanding of 
the process,[265] more confidently so after establishing their precursor role to hepatocytes,[266] and 
their localization in the canals of Hering[267] between bile capillaries and interlobular bile ducts (Figure 
2). A population of more committed hepatic stem/progenitor cells known as small hepatocytes had been 
first observed in rat cells in 1992,[268] and subsequently isolated from both adult rats[269] and 
humans.[270] 
Herrera et al. 2006[271], were able to isolate a human liver stem-like cell (HLSC) population expressing 
markers of mesenchymal (but not hematopoietic) stem cells from the tissues of adult human livers and 
from cryopreserved primary human hepatocytes. HLSCs showed the ability to self-renew and to 
differentiate into osteogenic, endothelial and insulin-producing cells, while starting with a partial 
commitment to the hepatocyte lineage. Since 2006, it has been regularly reported on HSLC and HLSC-
derived EVs.[88 97] 
 





For the isolation of EVs described in the following paragraph, HLSCs were cultured in the absence of 
FBS prior to cell culture medium collection, and their documented viability was between 97 and 99%, 
obviating concerns about co-isolation of FBS-EVs and limiting the presence of apoptotic bodies. 
The article by Herrera et al. from 2014[88 97] exemplifies the group s general preference of differential 
centrifugation (including UC)[88 97] for EV isolation: after performing two centrifugations at 3 000 x g 
for 20 min to remove cells and debris, EVs were isolated by 2 h UC (100 000 x g, 4°C). EVs were then 
either used fresh or after storing them at -80 °C (resuspended in RPMI with 5% (v/v) dimethyl sulfoxide). 
They provided precise storing conditions and reported no differences in the biochemical activity between 
freshly used and stored EVs.  
Variations of this protocol can be found in other articles published by this group. For example, Herrera 
had opted for a single centrifugation at 2 000  g for 20 min follo ed b  t o UC steps (100 000  g) of 1 
h each in 2010,[90] and then modified the protocol again to one centrifugation at 3 000  g for 20 min, a 
second one at 10 000  g for 1 h, and a final UC (100 000  g) for 1 h.[92] Gualerzi et al. 2019[97] added 
a size exclusion chromatography (SEC) purification step. 
Interestingly, Deregibus et al. in 2016[98] proposed an alternative approach by developing a custom 
charge-based strategy for EV isolation, in which they use protamine and PEG 35 kDa.[98] A comparison 
with commercially available precipitation kits was not performed, but their method yielded results that 
were  comparable to the UC approach in terms of EV-quality, and higher in terms of isolated EV-quantity  




Herrera et. al 2014 offers many of the characterization steps of HLSC-EV. Size distribution was 
determined by NTA. To trace EVs b  fluorescent microscop , EVs ere labeled ith 1 M Dil dye. 
Cytofluorimetric analysis was done using fluorescein isothiocyanate, phycoerythrin or allophycocyanin 
conjugated antibodies (CD73, CD44, CD105, CD90, CD107, CD63, CD29, CD81, CD146, HLA-class I). 
They also performed FACS after absorption on beads by incubating 10 g EVs with latex beads then 
with the aforementioned antibodies. EV protein content was quantified by Bradford assay; 
immunoblotting was also performed (CD63, CD81, Alix and Hsp9).  
Additional characterization for HLSC-EVs include zeta potential, TEM and analysis of RNA (Deregibus 
et al. 2016), as well as a novel method based on Raman spectroscopy for purity determination 
established by Gualerzi et al. 2019.[97] The method used Raman spectra to measure the protein-to-
lipid and nucleic acid-to-lipid ratios. 
 
7.3 Interspecies method transferability 
 
Liver stem cell EVs originating from rats have been described by Ichinohe et al. in 2017.[99] The liver 
resident stem/progenitor cells used were isolated by their research group before[272] (Thy1-positive 
cells[273]), but it is difficult to directly compare them to the HLSCs because there are no studies 
comparing their EVs. EVs from Thy+ cells were isolated using the commercially available precipitation 




spectrometer, since they administered 1.6 g of EVs to different li er cells and look at their effect on cell 
morphology, proliferation and IL17rb receptor expression. 
 
8. EVs from clinical settings 
 
There has been extensive research delving into the diagnostic potential of EVs in the context of liver-
associated conditions, albeit mostly looking into circulating vesicles, both in human patients[100 159] 
and in rodents.[215 251] The increased complexity of the system makes it difficult to trace their origin 
back to a specific cell type, but first efforts have been made to make that connection. We will highlight 
here research that endeavored to connect previously discussed in vitro settings to ex vivo findings. 
 
8.1 Isolation strategies 
 
Liver-derived EVs have been recovered in and ex vivo from liver blood directly,[160] bile[161] and even 
from cancer cells that were extracted intraoperatively.[162] The isolation of EVs from human patients 
mirrored protocols developed for cell culture systems, with differential centrifugation (including 
UC)[32,36 38,62,63,83,220] and polymer precipitation (ExoQuick  and TEI)[70,77,86,209,221] being 
the most prevalent approaches. Samples collected from blood circulation are consistently stored at -80 




Typically, the analysis of circulating EVs is focused on the biomarkers of interest. For example, Sohn et 
al. 2015[136] analysed the expression levels of serum exosomal microRNAs (miR-18a, -21, -93, -106b, 
-221, -222 and -224, -101, -122 and -195) of patients suffering from different liver conditions including 
chronic hepatitis B, liver cirrhosis and hepatocellular carcinoma. This also tends to happen when looking 
at specific cells. For example, Brandon-Warner et al. 2016,[70] who collected EVs from HSCs in vitro 
as well as from human plasma, performed RNA isolation using exoEasy  serum and plasma kit, 
followed by QiaZol total RNA purification; for exomes they only show miR data. 
 
8.3 Interspecies method transferability 
 
Nojima et al. 2016[66],[65] isolated EVs from primary mice hepatocytes and Kupffer cells in vitro by 
differential UC and sucrose gradient, while in the same studies describe also mice serum-derived EVs 
(even from cardiac puncture[65]) being isolated by ExoQuick . The isolation strategies were not 
transferred from in vitro to ex vivo in these cases, but the characterization practices (DLS for size, CD81-
antigen-ELISA for quantification) were.  
Lambrecht et al. 2017[77] evaluated the levels of miRNA-122, -150, -192, -21, -200b, and -92a by qRT-




was performed by TEI. Duan et al. 2019[62] compared compared findings from primary rat hepatocytes 
and human plasma. A wider comparison was performed by Hirsova et al. 2016:[63] Huh7 cells and 
primary mice hepatocytes both served as in vitro models in addition to their research with ex vivo human 
samples. In their research with cholangiocytes, Li X. et al. 2018[81] looked at EVs isolated from primary 
mice cells in vitro, but took it a step further ex vivo, evaluating both murine and human sera-derived 
EVs. Their methods included differential centrifugation (with a UC step) for EV-isolation, DLS and TEM 
for size analysis and assessment of mRNA H19 levels. Cho et al. 2017[32] isolated EVs from a variety 
of samples as well: human cell lines (HepG2, He3B), rat primary hepatocytes, human sera, rat sera. 
While differential centrifugation worked in vitro, they noted how extra steps were required ex vivo to 
reduce contamination with plasma proteins (e.g., albumin). EV isolation from plasma samples was thus 
optimized by comparing three alternative methods: density gradient UC (30% Optiprep), ExoQuick , 
and an optimized ExoQuick  protocol, which included 3 washing steps. Deregibus et al. 2016[98] were 
perhaps more interesting from a methodological transferability perspective, since they compared the 
performance of a custom charge-based precipitation method to differential UC, using samples derived 
from HLSCs (see chapter 7), human serum and human saliva.  
 
9. Final general remarks   
 
Strategies for liver-derived EV isolation and characterization are as varied as the research groups 
tackling the challenge. While the main advantages and disadvantages for each approach have been 
presented, we would like to highlight some of the key aspects that emerged.  
FBS handling. Cell culture approaches have become indispensable to simplify EV research before diving 
into significantly more complex ex vivo samples, but most cell lines require FBS for optimal growth. 
Depriving them of it might easily result in additional stress that will affect results to an unpredictable 
extent. Alternatives to FBS have already been proposed, such as  chemically defined media or human 
platelet lysate[274] and these may replace FBS-supplemented cell culture models.[275] Cells can be 
successively deprived of FBS to limit the impact of outright elimination of it, but more frequently than 
that, research groups opt to depleting their FBS of EVs by ultracentrifugation prior to use or they directly 
use commercially available ExoFreeFBS. The experimental validation for either of these steps is rarely 
reported, but it would be an important addition given the questionable efficacy of some the most common 
methods.[229] Even under serum-replacement conditions, miRNA contaminants have reportedly been 
found.[276] Whenever serums starvation (i.e., culturing without serum) is  feasible, it would be the 
preferred option.  
Cell viability. Looking at the EVs collected in vitro, the cell number and viability at EV-harvest are seldom 
mentioned. Depending on the study, 90-99% vital cells is what was deemed appropriate when 
documented at all.  As even a few dead cells can contribute to the presence of apoptotic bodies that 
can influence the EV-population it is important to report the number of viable cells in each study.[1]  
Yield. EV yield directly impacts the characterization possibilities because it determines whether there is 




isolation methods., revealing how well does a specific technique perform, especially when compared to 
alternatives. An absolute yield would also allow to evaluate upstream applicability, i.e., whether mass 
production would be a feasible option or not (e.g. for the use of liver-derived EVs as drug delivery 
systems). Because of all of these considerations, the importance of disclosing and being able to 
compare this data is easy to see, yet when looking at the quantification of EV-recovery, we found the 
information either omitted/lacking or hard to extrapolate and ultimately to compare between studies. The 
particle number per million cells measure would be a convenient option to express the yield and to 
compare its efficiency across studies. Quantification by mass of EV-associated proteins would also be 
viable alternative, if other co-isolated proteins can be excluded, preferably by number of cells as well. 
Storage. EV storage is a particularly relevant subject when EV isolation and characterization are not 
performed on the same day, which is often the case given how much time most of the described 
protocols require. Storage insights were not always provided, and their validation even less frequently. 
It has already been reported that storage modality can affect the EVs[277 279] which is why we think it 
is important to share this information. Trehalose, mannitol and polyethylene glycol had been evaluated 
as possible cryoprotectants in the aforementioned studies, although not in the context of liver-derived 
EVs as of yet. With the exception of dimethyl sulfoxide,[88 97] the use of cryoprotectants for storage 
below -20 °C is rarely considered.  
Differences in differential (ultra-)centrifugation. This isolation technique has become the gold standard 
in EV research for the very good reason that it works. It is cited in well over half the articles referenced 
in this review, but the protocols are not standardized. Even when analyzing EVs originating from the 
same cell types, different groups tend to have different approaches with sometimes unexplained 
differences arise within the same group which makes comparison challenging. The number of 
centrifugation steps vary and, the relative centrifugal forces and centrifugal times applied at each step 
are rarely consistent. When there is sufficient purity validation and subsequent sample characterization, 
this methodological diversity might not be an insurmountable issue, but it is worth keeping it in mind 
when comparing results, and also when choosing which protocol to follow. 
Suboptimal method description. There is a general lack of rigorous standardization of methods in EV 
research, that was addressed with a position paper first published in 2014,[280] then expended upon in 
2018.[1] EV-TRACK is a platform aiming at method transparency. Methods descriptions could be shared 
on EV-TRACK when the information would otherwise be left out of a publication. Implementing this 
would improve reproducibility and, more nuancedly, it would allow to compare method efficiencies 
across studies. Experimental validation of some practices is not always shared, which may be a problem 
when the methods used have been reported to have weaknesses, such as depletion of FBS-EVs. The 
growing community working on EVs is becoming more aware of the need for standardization in this 
young field of research,[281] and the MISEV guidelines[1] remain undoubtedly the reference text in 
these regards. 
 





We reviewed the current methodological practices for the isolation and analysis of those liver derived 
EVs, making a cell type specific user guide. Liver-derived EVs are gaining attention as a research topic, 
and there are already a few research papers addressing EVs from every liver resident cell type. Much 
work has already been published, but a rigorous standardization is needed. We moreover highlighted 
common causes for concern and critically reviewed room for improvement: the bigger issue that 
emerged was suboptimal method description and transparency.  
We found hepatocyte-derived EVs to be analyzed the most, perspective studies might tackle EVs 
originating from other cell types more frequently. EVs from human induced pluripotent stem cells (iPSC)-
derived hepatocyte like cells have not been analysed in detail yet, even though these cells are being 
taken under consideration as cell culture models for the liver.[282 284] EVs from iPSCs have been 
studied in the context of liver fibrosis, but they were still not differentiated into hepatocyte like cells.[285]  
The method transferability and translational applicability have also been a prominent topic of our 
discussion because working with EVs is inherently complicated even in single cell cultures, but many 
researchers have endeavored to escalate the challenge to co-cultures systems, to animal models 
(rodents), and to human patients. The comparisons have not always been complete, but the efforts put 
into positively tracing EVs and their associated biomolecules back to a specific cell type in increasingly 
more complex settings are a first important step to better understand liver diseases and we hope to see 
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